| Monofer (iron isomaltoside 1000) / Pharmacosmos |
NCT01900197: Time to Relapse of Iron Deficiency Anemia After Standard Treatment With a New Intravenous Iron (Monofer®) |
|
|
| Completed | N/A | 391 | Europe | 10% Iron Isomaltoside 1000, Monofer® | Pharmacosmos A/S, BioStata | Iron Deficiency Anemia | 11/15 | 11/15 | | |
DINO, NCT02301026: A Non-interventional Study of Diafer in Subjects With CKD on Haemodialysis for Treatment of Iron Deficiency |
|
|
| Completed | N/A | 209 | Europe | 5% Iron Isomaltoside 1000, Diafer® | Pharmacosmos A/S, BioStata | Anaemia in Chronic Kidney Disease | 12/16 | 12/16 | | |
NCT02546154: Time to Relapse of Iron Deficiency Anaemia After Standard Treatment With The Intravenous Iron (Monofer®) |
|
|
| Completed | N/A | 359 | Europe | 10% Iron Isomaltoside 1000, Monofer® | Pharmacosmos UK Ltd, BioStata | Iron Deficiency Anaemia | 12/18 | 12/18 | | |
Real-CHOICE, NCT04318405: Real Life Study on Iron Isomaltoside 1000 in the Treatment of ID in CKD, Heart Failure, ObGyn, IBD, Cancer and Elective Surgery (). |
|
|
| Completed | N/A | 327 | Europe | Iron isomaltoside 1000, Iron Derisomaltose 1000 | Pierre Fabre Pharma AG | Iron-Deficiency Anemia, Iron-Deficiency | 11/22 | 11/22 | | |
